Daily pill for lung cancer to be made routinely available on the NHS
The drug, Osimertinib—also known by its brand name Tagrisso and produced by AstraZeneca— which increases survival time ...
Daily pill on NHS offers new hope for hundreds with lung cancer
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...
J&J says its lung cancer drug combination keeps people alive longer
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...
J&J says cancer drug combination showed survival benefit over Tagrisso
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...
来自MSN28 天
AstraZeneca gets EU okay for Tagrisso for EGFR lung cancer
The European Commission approved Tagrisso for the treatment of adults with locally advanced, unresectable NSCLC whose tumors have ... treatment of various types of EGFR-mutation NSCLC.
Targeted Oncology13 天
FDA Grants Priority Review to Sunvozertinib in EGFR+ NSCLC
The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on ...
J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care
Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...
manilatimes13 天
U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy ...
Datopotamab deruxtecan granted Priority Review in the US for patients with previously ...
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...